Home > Blog Tag

Blog Posts by Tag: COVID-19

Lab Week 2021: Reflection and Gratitude

Once again, Lab week is upon us. As the second year celebrating Medical Laboratory Professionals Week (MLPW) in the midst of a global pandemic, it’s worth taking a moment to celebrate all our lab professionals and pathologists. Diagnostics is such a vital piece of the healthcare puzzle, and frontline laboratorians have been visible in unprecedented ways throughout the pandemic, but it is still...

Read


Preparing for Market Disruption – Operational Lessons From COVID-19

Conor WardVP of Sales, XIFIN Joe NollarAVP LIS Product Development, XIFIN In March 2021, we had the privilege of being interviewed by Linda Wilson, Senior Editor of Medical Laboratory Observer (MLO). The discussion focused on what has been learned by laboratories during the...

Read


After Large Spikes in 2020, Diagnostic Laboratory Testing Volumes on the Decline

As XIFIN CEO Lâle White wrote in her recent LinkedIn article, the COVID-19 pandemic created many challenges for the diagnostic industry in 2020. In the preceding years, many laboratories were running lean with little excess capacity. With the surge in COVID-19 testing demand, labs had to quickly add capacity to handle the new testing volume. In addition, dynamic regulatory changes designed...

Read


Payor Relations Insider: The Introduction of Turnaround Time Requirements for SARS–CoV–2 Testing

To ensure COVID testing is performed in as timely a manner as possible, CMS created a turnaround time-dependent reimbursement policy. Since its introduction in January 2021, many other payors have also adopted this pricing schema. The COVID-19 Public Health Emergency has created new burdens for clinical diagnostic laboratories. The results of these SARS-CoV-2 tests are used for critical treatment...

Read


HRSA High Throughput COVID-19 Claims: Correction Timeline

HHS confirmed there was a system error in the reimbursement for high throughput COVID-19 PCR testing claims, with HCPCS U0003 and U0004, for the HRSA COVID-19 Uninsured Patient Program. HHS indicated on their FAQ page they would not implement the add-on reimbursement for HCPCS U0005 on January 1, 2021 and would continue reimbursing independent laboratories at the rate of $100 for COVID-19...

Read


XIFIN LIS Keeps Laboratories Nimble: Responding Quickly to Fluctuations in COVID-19 Testing Demand and Turnaround Times

Early in the COVID-19 pandemic, laboratories were focused on the capabilities needed to get them ramped up quickly to handle COVID-19 testing. As 2020 wore on, labs were challenged to keep up with significant fluctuations in COVID testing volume, as well as ongoing shortages in test supplies.In October 2020, the Centers for Medicare & Medicaid Services (CMS) announced that starting January 1...

Read


Q&A Explores COVID's Impact on Lab Industry Testing Volumes and Dynamics

In a recent teleconference among XIFIN and UBS executives, XIFIN’s Chairman and CEO Lâle White and Chief Operating Officer Kyle Fetter discussed COVID-19's impact on lab industry testing volumes and dynamics.The one-hour conference revealed: Hospital volumes have come back stronger than any other sector Molecular volumes are doing well Genetic testing is continuing to increase with more...

Read


XIFIN Innovation Drives Growth in Four Critical Business Areas During COVID-19

Despite COVID-19's industry-altering effects on diagnostic labs and healthcare in general, XIFIN innovation in 2020 drove growth in four critical business areas: digital and genomic health, remote patient monitoring and medical device, healthcare informatics oncology, and traditional laboratory markets.XIFIN also generated notable client results and provided unique insights into lab testing...

Read